While this specialty pharma stock has not been outperforming the broader market year to date, there are several reasons to believe that will change – including recent FDA approval of its first and only treatment for a rare eye disease. CLICK HERE.
While this specialty pharma stock has not been outperforming the broader market year to date, there are several reasons to believe that will change – including recent FDA approval of its first and only treatment for a rare eye disease. CLICK HERE.